Étiquette : douleur

Is There a Role for Cannabis in Mental Health Disorders ? Pauline Anderson & Charles P. Vega, 2019

Is There a Role for Cannabis in Mental Health Disorders ? Pauline Anderson & Charles P. Vega, Medscape, CME / ABIM MOC / CE Released : 12/13/2019 https://www.medscape.org/viewarticle/922367   Clinical Context The most common indication for the use of medicinal cannabis is pain, although the results of studies of cannabis products for chronic pain are mixed. Häuser and colleagues performed a review of systematic reviews of cannabis for chronic pain conditions, and their results were published in the October 15, 2017 issue of European Journal of Pain.[1] Reviewers evaluated 10 systematic reviews of cannabis for pain. Methodological quality was high in 4 of the reviews. There was [...]

Lire la suite

Cannabinoids in Pain Management and Palliative Medicine, Winfried Häuser et al., 2017

Cannabinoids in Pain Management and Palliative Medicine An Overview of Systematic Reviews and Prospective Observational Studies Winfried Häuser, Mary-Ann Fitzcharles, Lukas Radbruch, Frank Petzke The Deutsches Ärzteblatt International,  2017, 114, 627–634. Doi : 10.3238/arztebl.2017.0627   SUMMARY Background : There are conflicting interpretations of the evidence regarding the efficacy, tolerability, and safety of cannabinoids in pain management and palliative medicine. Methods : We conducted a systematic review (SR) of systematic reviews of randomized controlled trials (RCT) and prospective long-term observational studies of the use of cannabinoids in pain management and palliative medicine. Pertinent publications from January 2009 to January 2017 were retrieved by a selective search in the Cochrane [...]

Lire la suite

The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain : How Cannabis Diminished Prescription Opioid Usage, Kevin M. Takakuwa et al., 2020

The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain : How Cannabis Diminished Prescription Opioid Usage Kevin M. Takakuwa, Jeffrey Y. Hergenrather, Frances S. Shofer, and Raquel M. Schears Cannabis and Cannabinoid Research, 2020, Volume X, Number X, 1-8. Doi : 10.1089/can.2019.0039 Abstract Objective : To determine if cannabis may be used as an alternative or adjunct treatment for intermittent and chronic prescription opioid users. Design : Retrospective cohort study. Setting : A single-center cannabis medical practice site in California. Patients : A total of 180 patients who had a chief complaint of low back pain were identified (International Classification of Diseases, 10th [...]

Lire la suite

Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms : Systematic review and meta-analysis, Jesse D. Kosiba et al., 2019

Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms : Systematic review and meta-analysis Jesse D. Kosiba, Stephen A. Maisto, Joseph W. Ditre Social Science & Medicine, 2019, 181-192. https://doi.org/10.1016/j.socscimed.2019.06.005 This study is the first to conduct a systematic review and meta-analysis of empirical studies that assess patient-reported reasons for using medical cannabis to alleviate pain, anxiety, and depression. The present review further assessed the quality of studies and identified several methodological flaws in extant research. Highlights •Systematically reviewed studies why patients use medical cannabis. •Pain was a common reason for medical cannabis use (64%). •Anxiety (50%) and depression (34%) were [...]

Lire la suite

Medical cannabis trial will target 20,000 UK patients, Jamie Doward and Lily Gordon Brown, The Guardian, 3 novembre 2019.

Medical cannabis trial will target 20,000 UK patients Jamie Doward and Lily Gordon Brown The GUARDIAN, Published on Sun 3 Nov 2019 https://www.theguardian.com/society/2019/nov/03/medical-cannabis-uk-clinical-trial-patients-nhs   Project backed by Royal College of Psychiatrists aims to be largest on drug’s use in Europe • Medical cannabis: Why are doctors still not prescribing it? Tilray medicinal cannabis growing facility in Canada. Photograph: Tilray Up to 20,000 patients in the UK are to be given medical cannabis over a two-year period in an initiative that aims to create the largest body of evidence on the drug in Europe. The move, to be unveiled on Thursday, is [...]

Lire la suite

Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD : A Randomized, Double-Blind Trial, Aleksandra Nitecka-Buchta et al., 2019

Myorelaxant Effect of Transdermal Cannabidiol Application in Patients with TMD : A Randomized, Double-Blind Trial Aleksandra Nitecka-Buchta, Anna Nowak-Wachol, KacperWachol, KarolinaWalczynska-Dragon, Paweł Olczyk, Olgierd Batoryna, Wojciech Kempa and Stefan Baron Journal of Clinical Medicine, 2019, 8, 188, 1-17. doi : 10.3390/jcm8111886 Abstract Background : The healing properties of cannabidiol (CBD) have been known for centuries. In this study, we aimed to evaluate the efficiency of the myorelaxant effect of CBD after the transdermal application in patients with myofascial pain. Methods : The Polish version of the Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD Ia and Ib) was used. A total of 60 patients were enrolled [...]

Lire la suite

A spider derived peptide, PnPP-19, induces central antinociception mediated by opioid and cannabinoid systems, Daniela da Fonseca Pacheco et al.,

A spider derived peptide, PnPP-19, induces central antinociception mediated by opioid and cannabinoid systems Daniela da Fonseca Pacheco, Ana Cristina Nogueira Freitas, Adriano Monteiro C. Pimenta, Igor Dimitri Gama Duarte and Maria Elena de Lima Journal of Venomous Animals and Toxins including Tropical Diseases, 2016, 22, 34, Doi : 10.1186/s40409-016-0091-6   Abstract Background : Some peptides purified from the venom of the spider Phoneutria nigriventer have been identified as potential sources of drugs for pain treatment. In this study, we characterized the antinociceptive effect of the peptide PnPP-19 on the central nervous system and investigated the possible involvement of opioid and cannabinoid systems in its action [...]

Lire la suite

Chemistry, pharmacology and medicinal properties of Peganum harmala L., Jinous Asgarpanah and Fereshteh Ramezanloo, 2012

Chemistry, pharmacology and medicinal properties of Peganum harmala L. Jinous Asgarpanah and Fereshteh Ramezanloo African journal of pharmacy and pharmacology, 2012, 6, (22), 1573-1580. Doi : 10.5897/AJPP11.876   Peganum harmala L. is known as Syrian rue, Wild rue and Harmal. P. harmala extracts are considered important for drug development, because they are reported to have numerous pharmacological activities in the Middle East, especially in Iran and Egypt. For a long time P. harmala has been used in traditional medicines for the relief of pain and as an antiseptic agent. P. harmala also have antibacterial, antifungal, antiviral, antioxidant, antidiabetic, antitumor, antileishmanial, insecticidal and cytotoxic activities and hepatoprotective and antinociceptive effects. Harmaline, [...]

Lire la suite

Safety and Efficacy of Medical Cannabis in Fibromyalgia, Iftach Sagy et al., 2019

Safety and Efficacy of Medical Cannabis in Fibromyalgia Iftach Sagy, Lihi Bar-Lev Schleider, Mahmoud Abu-Shakra and Victor Novack Journal of Clinical Medicine, 2019, 8, 807 doi : 10.3390/jcm8060807   Abstract : Background : Chronic pain may be treated by medical cannabis. Yet, there is scarce evidence to support the role of medical cannabis in the treatment of fibromyalgia. The aim of the study was to investigate the characteristics, safety, and eectiveness of medical cannabis therapy for fibromyalgia. Methods : A prospective observational study with six months follow-up period based on fibromyalgia patients who were willing to answer questionnaire in a specialized medical cannabis clinic between 2015 and 2017. Results : Among the [...]

Lire la suite

Medicinal properties of Peganum harmala L. in traditional Iranian medicine and modern phytotherapy : a review, Mina Cheraghi Niroumand et al., 2015

Medicinal properties of Peganum harmala L. in traditional Iranian medicine and modern phytotherapy: a review Mina Cheraghi Niroumand, Mohammad Hosein Farzaei, Gholamreza Amin Journal of Traditional Chinese Medicine, 2015, 35, (1), 104-109.   Abstract OBJECTIVE : To review the pharmacological activities of Peganum harmala L. (P. harmala, Nitrariaceae) in traditional Iranian medicine (TIM) and modern phytotherapy. METHODS : Opinions of TIM and modern phytotherapy about safety and acceptable dosage of this plant are discussed. Various medical properties of P. harmala were collected from important TIM references and added to scientific reports derived from modern medical databases like PubMed, Scirus, ScienceDirect and Scopus. RESULTS : The main medicinal [...]

Lire la suite